These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32274629)

  • 1. Intratumor injection of CCL21-coupled vault nanoparticles is associated with reduction in tumor volume in an in vivo model of glioma.
    Voth BL; Pelargos PE; Barnette NE; Bhatt NS; Chen CHJ; Lagman C; Chung LK; Nguyen T; Sheppard JP; Romiyo P; Mareninov S; Kickhoefer VA; Yong WH; Rome LH; Yang I
    J Neurooncol; 2020 May; 147(3):599-605. PubMed ID: 32274629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth.
    Kar UK; Srivastava MK; Andersson A; Baratelli F; Huang M; Kickhoefer VA; Dubinett SM; Rome LH; Sharma S
    PLoS One; 2011 May; 6(5):e18758. PubMed ID: 21559281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
    Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
    Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival.
    Belmans J; Van Woensel M; Creyns B; Dejaegher J; Bullens DM; Van Gool SW
    Sci Rep; 2017 Oct; 7(1):13902. PubMed ID: 29066810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioengineered recombinant vault nanoparticles coupled with NY-ESO-1 glioma-associated antigens induce maturation of native dendritic cells.
    Nagasawa DT; Yang J; Romiyo P; Lagman C; Chung LK; Voth BL; Duong C; Kickhoefer VA; Rome LH; Yang I
    J Neurooncol; 2020 May; 148(1):1-7. PubMed ID: 32383063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Machine Learning-Directed Conversion of Glioblastoma Cells to Dendritic Cell-Like Antigen-Presenting Cells as Cancer Immunotherapy.
    Liu T; Jin D; Le SB; Chen D; Sebastian M; Riva A; Liu R; Tran DD
    Cancer Immunol Res; 2024 Oct; 12(10):1340-1360. PubMed ID: 39051633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral delivery of bortezomib: impact on survival in an intracranial glioma tumor model.
    Wang W; Cho HY; Rosenstein-Sisson R; Marín Ramos NI; Price R; Hurth K; Schönthal AH; Hofman FM; Chen TC
    J Neurosurg; 2018 Mar; 128(3):695-700. PubMed ID: 28409734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice.
    Pellegatta S; Poliani PL; Corno D; Grisoli M; Cusimano M; Ubiali F; Baggi F; Bruzzone MG; Finocchiaro G
    Neurol Res; 2006 Jul; 28(5):527-31. PubMed ID: 16808884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
    Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A therapeutic cancer vaccine against GL261 murine glioma.
    Kindy MS; Yu J; Zhu H; Smith MT; Gattoni-Celli S
    J Transl Med; 2016 Jan; 14():1. PubMed ID: 26727970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells.
    Authier A; Farrand KJ; Broadley KW; Ancelet LR; Hunn MK; Stone S; McConnell MJ; Hermans IF
    Int J Cancer; 2015 Jun; 136(11):2566-78. PubMed ID: 25363661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical Modeling of Surgery and Steroid Therapy for Glioblastoma Reveals Changes in Immunophenotype that are Associated with Tumor Growth and Outcome.
    Otvos B; Alban TJ; Grabowski MM; Bayik D; Mulkearns-Hubert EE; Radivoyevitch T; Rabljenovic A; Johnson S; Androjna C; Mohammadi AM; Barnett GH; Ahluwalia MS; Vogelbaum MA; Fecci PE; Lathia JD
    Clin Cancer Res; 2021 Apr; 27(7):2038-2049. PubMed ID: 33542075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.
    Karachi A; Yang C; Dastmalchi F; Sayour EJ; Huang J; Azari H; Long Y; Flores C; Mitchell DA; Rahman M
    Neuro Oncol; 2019 Jun; 21(6):730-741. PubMed ID: 30668768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of immunomodulation in human glioblastoma.
    Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
    Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.
    Woroniecka KI; Rhodin KE; Dechant C; Cui X; Chongsathidkiet P; Wilkinson D; Waibl-Polania J; Sanchez-Perez L; Fecci PE
    Clin Cancer Res; 2020 Mar; 26(6):1349-1358. PubMed ID: 31871298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into CCL21's roles in immunosurveillance and immunotherapy for gliomas.
    Nguyen T; Lagman C; Chung LK; Chen CH; Poon J; Ong V; Voth BL; Yang I
    J Neuroimmunol; 2017 Apr; 305():29-34. PubMed ID: 28284342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Safety of available immunotherapy for the treatment of glioblastoma.
    Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
    Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological Aspects of Malignant Gliomas.
    Cohen-Inbar O; Zaaroor M
    Can J Neurol Sci; 2016 Jul; 43(4):494-502. PubMed ID: 27324313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma.
    Maggio D; Ho WS; Breese R; Walbridge S; Wang H; Cui J; Heiss JD; Gilbert MR; Kovach JS; Lu RO; Zhuang Z
    J Neurooncol; 2020 Jun; 148(2):231-244. PubMed ID: 32342332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.